Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Healthcare
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care... see more

Recent & Breaking News (NDAQ:SNOA)

Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products

GlobeNewswire April 17, 2018

Mid-Morning Market Update: Markets Open Higher; Monsanto Earnings Miss Expectations

Benzinga.com  April 5, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 5, 2018

Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel

GlobeNewswire April 5, 2018

Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution

GlobeNewswire March 27, 2018

Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018

GlobeNewswire March 9, 2018

Dawson James Securities Announces Closing of $5 Million Public Offering for Sonoma Pharmaceuticals, Inc.

Accesswire March 7, 2018

Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock

GlobeNewswire March 6, 2018

Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock

GlobeNewswire March 2, 2018

Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%

GlobeNewswire February 7, 2018

Sonoma Pharmaceuticals, Inc. to Host Earnings Call

Accesswire February 7, 2018

Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call

GlobeNewswire January 25, 2018

Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis

GlobeNewswire January 9, 2018

Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis

GlobeNewswire December 5, 2017

Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language

GlobeNewswire November 16, 2017

Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million

GlobeNewswire November 9, 2017

Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products

GlobeNewswire October 31, 2017

Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call

GlobeNewswire October 26, 2017

Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis

GlobeNewswire October 3, 2017

Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan

GlobeNewswire September 14, 2017